Your Health, We Care
Most common adverse reactions (≥ 40%) are: vomiting, rash (all), abdominal pain, diarrhea, nausea, dry skin, fatigue, musculoskeletal pain, pyrexia, acneiform rash, stomatitis, headache, paronychia, and pruritus.
from FDA，2024.01
Selumetinib is used to treat type 1 neurofibromatosis (NF1) in pediatric patient···【more】
Release date：2026-02-10Recommended：37
Selumetinib is used to treat patients with neurofibromatosis type 1 (NF1) with p···【more】
Release date：2026-02-10Recommended：33
By targeting and inhibiting the activity of MEK protein, Koselugo effectively cu···【more】
Release date：2024-08-23Recommended：296
Koselugoinhibits tumor cell proliferation by inhibiting MEK protein activity, bl···【more】
Release date：2024-08-23Recommended：251
Koselugo is a targeted therapy drug primarily used to treat a specific subtype o···【more】
Release date：2024-08-23Recommended：278
